Personalizing health care: feasibility and future implications

Hdl Handle:
http://hdl.handle.net/10147/305321
Title:
Personalizing health care: feasibility and future implications
Authors:
Godman, Brian; Finlayson, Alexander E; Cheema, Parneet K; Zebedin-Brandl, Eva; Gutiérrez-Ibarluzea, Inaki; Jones, Jan; Malmström, Rickard E; Asola, Elina; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrario, Alessandra; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Lööv, Sven-Ake; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahovic-Palcevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars L
Citation:
BMC Medicine. 2013 Aug 13;11(1):179
Journal:
BMC medicine
Issue Date:
13-Aug-2013
URI:
http://dx.doi.org/10.1186/1741-7015-11-179; http://hdl.handle.net/10147/305321
Abstract:
Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.
Language:
en
Keywords:
HEALTH CARE; PATIENT SATISFACTION; QUALITY IMPROVEMENT

Full metadata record

DC FieldValue Language
dc.contributor.authorGodman, Brianen_GB
dc.contributor.authorFinlayson, Alexander Een_GB
dc.contributor.authorCheema, Parneet Ken_GB
dc.contributor.authorZebedin-Brandl, Evaen_GB
dc.contributor.authorGutiérrez-Ibarluzea, Inakien_GB
dc.contributor.authorJones, Janen_GB
dc.contributor.authorMalmström, Rickard Een_GB
dc.contributor.authorAsola, Elinaen_GB
dc.contributor.authorBaumgärtel, Christophen_GB
dc.contributor.authorBennie, Marionen_GB
dc.contributor.authorBishop, Iainen_GB
dc.contributor.authorBucsics, Annaen_GB
dc.contributor.authorCampbell, Stephenen_GB
dc.contributor.authorDiogene, Eduardoen_GB
dc.contributor.authorFerrario, Alessandraen_GB
dc.contributor.authorFürst, Jurijen_GB
dc.contributor.authorGaruoliene, Kristinaen_GB
dc.contributor.authorGomes, Miguelen_GB
dc.contributor.authorHarris, Katharineen_GB
dc.contributor.authorHaycox, Alanen_GB
dc.contributor.authorHerholz, Haralden_GB
dc.contributor.authorHviding, Krystynaen_GB
dc.contributor.authorJan, Sairaen_GB
dc.contributor.authorKalaba, Marijaen_GB
dc.contributor.authorKvalheim, Christinaen_GB
dc.contributor.authorLaius, Otten_GB
dc.contributor.authorLööv, Sven-Akeen_GB
dc.contributor.authorMalinowska, Kamilaen_GB
dc.contributor.authorMartin, Andrewen_GB
dc.contributor.authorMcCullagh, Lauraen_GB
dc.contributor.authorNilsson, Fredriken_GB
dc.contributor.authorPaterson, Kenen_GB
dc.contributor.authorSchwabe, Ulrichen_GB
dc.contributor.authorSelke, Gisberten_GB
dc.contributor.authorSermet, Catherineen_GB
dc.contributor.authorSimoens, Stevenen_GB
dc.contributor.authorTomek, Dominiken_GB
dc.contributor.authorVlahovic-Palcevski, Veraen_GB
dc.contributor.authorVoncina, Lukaen_GB
dc.contributor.authorWladysiuk, Magdalenaen_GB
dc.contributor.authorvan Woerkom, Mennoen_GB
dc.contributor.authorWong-Rieger, Durhaneen_GB
dc.contributor.authorZara, Corrineen_GB
dc.contributor.authorAli, Raghiben_GB
dc.contributor.authorGustafsson, Lars Len_GB
dc.date.accessioned2013-11-13T10:31:53Z-
dc.date.available2013-11-13T10:31:53Z-
dc.date.issued2013-08-13-
dc.identifier.citationBMC Medicine. 2013 Aug 13;11(1):179en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1741-7015-11-179-
dc.identifier.urihttp://hdl.handle.net/10147/305321-
dc.description.abstractAbstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.-
dc.language.isoenen
dc.subjectHEALTH CAREen_GB
dc.subjectPATIENT SATISFACTIONen_GB
dc.subjectQUALITY IMPROVEMENTen_GB
dc.titlePersonalizing health care: feasibility and future implicationsen_GB
dc.identifier.journalBMC medicineen_GB
dc.language.rfc3066en-
dc.rights.holderBrian Godman et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2013-11-13T05:09:20Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.